Sirolimus Reduces T Cell Cycling, Immune Checkpoint Marker Expression, and HIV-1 DNA in People with HIV

Scientists evaluated the safety of sirolimus in people with HIV (PWH) and study the impact of sirolimus on HIV-1 reservoir size and HIV-1-specific immunity in a single-arm study of 20 weeks of treatment in PWH on antiretroviral therapy.